87 related articles for article (PubMed ID: 20432623)
1. Serum-derived immunoglobulins alter amyloid beta transport across a blood-brain barrier in vitro model.
Poetsch V; Bennani-Baiti B; Neuhaus W; Muchitsch EM; Noe CR
Pharmazie; 2010 Apr; 65(4):267-73. PubMed ID: 20432623
[TBL] [Abstract][Full Text] [Related]
2. Serum-derived immunoglobulins neutralize adverse effects of amyloid-beta peptide on the integrity of a blood-brain barrier in vitro model.
Poetsch V; Neuhaus W; Noe CR
J Alzheimers Dis; 2010; 21(1):303-14. PubMed ID: 20421696
[TBL] [Abstract][Full Text] [Related]
3. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
4. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
[TBL] [Abstract][Full Text] [Related]
6. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein.
Candela P; Gosselet F; Saint-Pol J; Sevin E; Boucau MC; Boulanger E; Cecchelli R; Fenart L
J Alzheimers Dis; 2010; 22(3):849-59. PubMed ID: 20858979
[TBL] [Abstract][Full Text] [Related]
7. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.
Bates KA; Verdile G; Li QX; Ames D; Hudson P; Masters CL; Martins RN
Mol Psychiatry; 2009 May; 14(5):469-86. PubMed ID: 18794889
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier.
Li M; Shang DS; Zhao WD; Tian L; Li B; Fang WG; Zhu L; Man SM; Chen YH
J Immunol; 2009 May; 182(9):5778-88. PubMed ID: 19380826
[TBL] [Abstract][Full Text] [Related]
9. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
Wang YJ; Zhou HD; Zhou XF
Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
[TBL] [Abstract][Full Text] [Related]
10. Epitope-dependent effects of Beta-amyloid antibodies on Beta-amyloid clearance in an in vitro model of the blood-brain barrier.
Bachmeier CJ; Beaulieu-Abdelahad D; Mullan MJ; Paris D
Microcirculation; 2011 Jul; 18(5):373-9. PubMed ID: 21418385
[TBL] [Abstract][Full Text] [Related]
11. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
Solomon B
Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
[TBL] [Abstract][Full Text] [Related]
12. Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma.
Mare S; Penugonda S; Robinson SM; Dohgu S; Banks WA; Ercal N
Peptides; 2007 Jul; 28(7):1424-32. PubMed ID: 17580097
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease.
Donahue JE; Johanson CE
J Neuropathol Exp Neurol; 2008 Apr; 67(4):261-70. PubMed ID: 18379441
[TBL] [Abstract][Full Text] [Related]
14. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
Deane R; Wu Z; Sagare A; Davis J; Du Yan S; Hamm K; Xu F; Parisi M; LaRue B; Hu HW; Spijkers P; Guo H; Song X; Lenting PJ; Van Nostrand WE; Zlokovic BV
Neuron; 2004 Aug; 43(3):333-44. PubMed ID: 15294142
[TBL] [Abstract][Full Text] [Related]
15. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway.
Ito S; Ueno T; Ohtsuki S; Terasaki T
J Neurochem; 2010 Jun; 113(5):1356-63. PubMed ID: 20367755
[TBL] [Abstract][Full Text] [Related]
16. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.
Poduslo JF; Curran GL; Wengenack TM; Malester B; Duff K
Neurobiol Dis; 2001 Aug; 8(4):555-67. PubMed ID: 11493021
[TBL] [Abstract][Full Text] [Related]
17. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
Deane R; Du Yan S; Submamaryan RK; LaRue B; Jovanovic S; Hogg E; Welch D; Manness L; Lin C; Yu J; Zhu H; Ghiso J; Frangione B; Stern A; Schmidt AM; Armstrong DL; Arnold B; Liliensiek B; Nawroth P; Hofman F; Kindy M; Stern D; Zlokovic B
Nat Med; 2003 Jul; 9(7):907-13. PubMed ID: 12808450
[TBL] [Abstract][Full Text] [Related]
18. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes.
Ito S; Ohtsuki S; Kamiie J; Nezu Y; Terasaki T
J Neurochem; 2007 Dec; 103(6):2482-90. PubMed ID: 17908238
[TBL] [Abstract][Full Text] [Related]
19. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk.
Takechi R; Galloway S; Pallebage-Gamarallage MM; Lam V; Mamo JC
Prog Lipid Res; 2010 Apr; 49(2):159-70. PubMed ID: 19896503
[TBL] [Abstract][Full Text] [Related]
20. Natural human antibodies to amyloid beta peptide.
Szabo P; Relkin N; Weksler ME
Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
